MicroRNA-21 (miR-21) is overexpressed virtually in all human
Introduction
One of the most frequently mutated genes in human cancer is the tumor suppressor p53 gene, which is widely regarded as the 'guardian of the genome' (1). p53 is a transcription factor that regulates the expression of a battery of genes that control cell cycle progression and apoptosis in response to DNA damage or cellular stress. There are two homologs of p53: p63 (TP73L) and p73 (TP73), which have a similar tumor suppressor activity as p53 (2) . Mice lacking p53 (also known as Trp53) are prone to spontaneous tumor formation and develop lymphoma and sarcoma with a short latency (3, 4) . Restoring p53 function alone is sufficient to cause regression of several different tumors in mice with Trp53 deletion (5-7), supporting the possibility of p53 as a therapeutic target. However, over 30 years after the discovery of p53, no effective anticancer treatment based on p53 has yet been developed.
MicroRNAs (miRs) suppress their target genes through binding the 3′ untranslated regions of messenger RNAs. Several miRs were reported to be involved in the p53 pathway, either regulated by p53 or acting directly to repress the expression of p53 or its downstream effectors, suggesting the importance of miRs in the p53 pathway (8) (9) (10) (11) (12) (13) (14) . miR-21 is overexpressed in virtually all solid tumors (15) (16) (17) , and recent studies have also shown that miR-21 is highly expressed in hematological malignancies such as leukemia (18) , lymphoma (19) and multiple myeloma (20) . Several studies using cell lines reveal that knockdown of miR-21 results in reduced tumor cell growth (21) , cell cycle arrest (22) and cell apoptosis (23) . Three independent groups corroborated the role of miR-21 in carcinogenesis using genetically engineered mouse models. Overexpression of miR-21 leads to pre-B malignant lymphoid-like phenotype (24) and enhances Kras-driven lung tumorigenesis (25) , whereas genetic deletion of miR-21 partially reduced the incidence and growth of Kras-driven lung tumors (25) and genotoxic carcinogen-induced skin carcinogenesis (26) . Collectively, these data suggest that miR-21 is an oncomiR (an oncogenic miR).
There is no miR-21 binding site in the p53 3′ untranslated region in either human or mouse, yet there are several reports demonstrating that miR-21 represses the expression of multiple genes in the p53 network. Downregulation of miR-21 in glioblastoma cells leads to elevated expression of p63 and activators of the p53 pathway, including JMY, TOPORS, TP53BP2 and DAXX, causing cell cycle arrest and increasing apoptosis (27) . In breast cancer cells, miR-21 inhibition induces the expression of several genes regulated by p53 at the messenger RNA level, including FAM3C, ACTA2, APAF1, BTG2, FAS, CDKN1A(p21) and SESN1 (28) . These genes are required for p53 activity, suggesting that miR-21 overexpression could impair the tumor-suppressive function of the p53 pathway. A recent study reports that miR-21 expression is elevated in human lung tumors bearing mutated p53 and displaying distant metastases and that augmented expression of miR-21 confers increased invasive properties in Trp53-deficient mouse tumors (29) . However, the functional interaction between p53 and miR-21 in vivo has remained elusive. In this study, we intercrossed miR-21 −/− and Trp53 −/− mice to study the interplay between miR-21 and the p53 pathway in tumorigenesis. In addition, we used cultured mouse embryonic fibroblast cells (MEFs) to characterize the functional overlap between miR-21 and the p53 pathway. This work deepens our understanding of the association between a critical oncomiR and the p53 tumor suppressor network and offers new strategies for cancer therapy. . It was estimated that all mice had >90% C57BL/6 genetic background (C57BL/6 × 129S hybrid background with three backcross). All experimental procedures involving animals in this study were approved by the institutional animal care and use committee at the University of Louisville.
Materials and methods

Generation of Trp53
MEF preparation
MEFs were prepared according to an established protocol (30) . MEFs were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino acids and incubated at 37°C in a 5% CO 2 atmosphere. To measure cell growth, MEFs were seeded at 1 × 10 5 cell density, which was designated as day 1 (d1) and cells were counted at days 4, 6, 8 and 10. (8) (9) (10) weeks of age, 6 mice per group) were used for in vivo apoptosis study. Doxorubicin was dissolved in dimethyl sulfoxide at 10 mg/ml and administered intraperitoneally at 5 mg/kg. After 24 h, mice were killed. Spleens were collected and fixed with 10% neutral-buffered formalin. Deparaffinized sections were incubated with 20 µg/ml protease K for 15 min at room temperature, and then washed with PBS and incubated with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) reaction mixture (Roche Diagnostics, Indianapolis, IN) for 60 min at 37°C in humidified atmosphere. For MEF apoptosis analysis, cells were treated with 1 µmol/l (0.58 µg/ ml) doxorubicin; cells were collected and fixed with 4% paraformaldehyde, and then incubated with 3% H 2 O 2 , 0.1% Triton X-100 and TUNEL reaction mixture. Tissue sections or fixed cells were finally incubated with converter-POD (with antifluorescein antibody) and subsequently with the diaminobenzidene substrate. Images were acquired using Olympus IX51 microscope and cellSens Dimension software. Nuclei with condensed or fragmented chromatin (brown color) were considered apoptotic death; at least 5000 cells were counted under microscopy with 20× objective lens in each group.
Flow cytometry
Cell senescence
MEFs were split into six-well plates with a density of 1 × 10 5 cells every passage. And at passage 2 (P2), P8 and P12, MEFs were collected and senescence was determined by measuring β-galactosidase with Senescence β-Galactosidase Staining Kit (Cell Signaling, Danvers, MA) according to the manufacturer's protocols.
Cell transformation and focus-forming assay P2 MEFs were infected with a retroviral vector pBabe H-Ras (#1768; Addgene, Cambridge, MA) containing an activated H-ras V12 complementary DNA and puromycin resistance gene. After 2 µg/ml puromycin selection, 2000 cells were cultured in six-well plates. On day 21, the cells were fixed with 70% ethanol and stained with crystal violet. The foci were counted under microscopy with 4× objective lens.
Western blotting
Cells were lysed with RIPA buffer (Cell Signaling) supplemented with protease inhibitor (Calbiochem, San Diego, CA). Soluble proteins were subjected to 
Statistical analysis
Average data were expressed as mean and standard deviation. Statistical analysis was carried out using the SPSS16.0 software (SPSS, Chicago, IL). The one-way analysis of variance test was performed and statistical significance was set at *P < 0.05 or **P < 0.01. All experiments were performed using two or more independent MEF preparations. *P < 0.05; **P < 0.01; NS, not significant.
Results
Generation of Trp53
Analysis of survival and spontaneous tumor development
Mice with the four genotypes were maintained to determine spontaneous tumor development and survival. WT and miR-21 −/− mice were monitored for over 18 months and no tumors were found. The average life span of Trp53 −/− mice was previously reported to be ~160 days (32) and was 169 days in our animal cohort. We found that the average survival for Trp53 −/− miR-21 −/− mice was longer (195 days), but this was not statistically significant (P = 0.199; Figure 1C Figure 1D and Supplementary (Figure 2A ). These data suggest that deletion of miR-21 does not affect cell proliferation of Trp53
−/−
MEFs, yet miR-21 loss did reduce cell proliferation of WT MEFs.
p53 plays a crucial role in cellular senescence, which is a permanent form of cell cycle arrest in primary cultured cells. Unlike WT MEFs treated with doxorubicin. *P < 0.05; **P < 0.01; NS, not significant.
MEFs, MEFs lacking p53 do not undergo cellular senescence (34 Figure 2D ), which is in agreement with a previous study (35) . There was no significant difference in G 1 Figure 2E ). These data suggest that miR-21 did not significantly impact G 1 cell arrest induced by DNA damage.
Apoptosis in vivo and in vitro
p53 plays a key role in antilymphomagenesis through apoptosis (36) , and miR-21 performs its oncomiR function by inhibiting apoptosis (24) . We determined the frequency of cellular apoptosis in mouse tissues responding to DNA damage. Spleen is one of the most sensitive organs to DNA damage-induced cell apoptosis (37) . Mice were treated with doxorubicin for 24 h and apoptosis in the spleen was analyzed using TUNEL. For each group, more apoptotic cells were found in the spleens of mice receiving doxorubicin treatment than in untreated mice ( Figure 3A and B) . As expected, a low level of apoptosis was observed in the spleens of p53-null mice upon treatment than in other groups. There were more apoptotic cells in miR-21 Figure 3A and B) . These in vivo data support the notion that miR-21 deletion sensitizes cells to apoptosis induced by DNA-damaging agents, either in the presence or in the absence of p53.
We next examined the apoptosis response using MEFs. We found more apoptotic cells for Trp53 Figure 3E ). Collectively, these data suggest that miR-21 has an antiapoptosis role in cells lacking p53, which is in line with previous reports that miR-21 deletion increases cellular apoptosis in cells with the WT p53 gene (24) (25) (26) . 
Deletion of miR-21 inhibits Ras-induced transformation in p53-null MEFs
MEFs lacking p53 have been reported to evade Ras-induced senescence (38) , whereas miR-21 deletion suppresses SV40LT and Ras-driven transformation (25) . We next explored the role of miR-21 in Ras-driven transformation in the absence of p53. We introduced a retroviral vector, pBabe H-Ras, which contains an activated H-ras Figure 5D ).
The convergence of miR-21 with the p53 pathway in apoptosis
To further explore the interplay between p53 and miR-21 in apoptosis, we analyzed the expression of p53 transactivational genes Puma and Bax (which are well known to participate in apoptosis), p63 and p73 (which are homologs of the p53 protein) and several reported miR-21 target genes. Although we did observe that p73 and Puma were downregulated when p53 was deleted, miR-21 ablation did not appear to affect the expression of genes in the p53 pathway (left panel, Figure 5A ). Among miR-21 targets, Pten and Pdcd4 were upregulated upon miR-21 deletion, regardless of p53 status (right panel, Figure 5A ).
Next, we treated MEFs with doxorubicin and analyzed the protein levels of Pten and Pdcd4. We found that Pdcd4 expression levels were higher in Trp53 Figure 5B ). In the presence of p53, Pten levels changed little, whereas Pdcd4 levels were downregulated significantly in WT and miR -21 −/− cells upon doxorubicin treatment (right panel, Figure 5B ). These data suggest that Pten is the likely miR-21 target that participates in changes in apoptosis, as its expression levels follow that of cellular apoptosis when p53 is absent. Finally, we inhibited Pten expression in Trp53
−/− cells using small interfering RNA (siRNAs) ( Figure 5C ) to determine whether reduced Pten expression would rescue the increased apoptosis upon miR-21 loss. We found fewer apoptotic cells when Pten was downregulated ( Figure 5D and E), which confirms the critical role of Pten in linking miR-21 with p53-independent apoptosis.
Discussion
Recent clinical and laboratory studies have implicated miR-21 in the pathogenesis of various diseases, especially in many cancers (39) . miR-21 overexpression is observed in most, if not all, types of carcinomas and hematological malignancies, and it is considered to be one of the most promising oncomiRs for targeted cancer therapy. p53 is a major tumor suppressor in cancer, as it is mutated in about half of all human malignancies. In this study, we have investigated whether miR-21 plays a role in mouse tumorigenesis mediated by loss of p53. We found that there is no significant difference in animal survival and tumor spectrum between Trp53 −/− and Trp53 −/− miR-21 −/− mice (P = 0.199), which are comparable with Kras-induced lung tumorigenesis (25) . In that model, miR-21 overexpression causes more tumors and miR-21 deletion leads to fewer tumors in the lung, yet miR-21 overexpression does not significantly impact animal survival (P = 0.357). miR-21 deletion reduces the number of Kras-induced lung tumors, though the survival curve for miR-21-deficient mice with Kras activation compared with the control has not been reported (25) . These data suggest that p53 knockout or Kras activation may be a tumorigenesis driver that is too strong for miR-21 deletion to override and thereby reduce tumor burden.
We next analyzed the cellular processes regulated by p53. Lack of p53 leads to defective cell cycle arrest, spontaneous immortalization and attenuated apoptosis (40) . Our data obtained from Trp53
MEFs show that ablation of miR-21 does not impact G 1 arrest, yet it slightly enhances senescence of MEFs at P8. However, the expression of p21, an executor of cell senescence, is not altered by miR-21 deletion, suggesting that other unknown genes regulated by miR-21 may play a role in p53-independent cellular senescence.
Apoptosis is a critical cellular process induced by p53, which functions as a tumor suppressor gene in response to DNA damage (41) . All miR-21 transgenic or knockout murine models reveal that miR-21 exercises its oncogenic function through decreased apoptosis (24) (25) (26) . In several human cancer cell lines, miR-21 inhibition leads to increased cellular apoptosis (15, 27, (42) (43) (44) (45) We next investigated which miR-21 target is responsible for the increased apoptosis, particularly in cells without the Trp53 gene. Pten has been verified as a miR-21 target in hepatocellular cancer, squamous cell carcinoma and pancreatic cancer (46) (47) (48) . Interestingly, Pten is transactivated by p53 and is required for p53-mediated apoptosis in immortalized MEFs (49), yet we did not observe significant downregulation of Pten when p53 was deleted ( Figure 5A ). Our data in this and a previous study show that Pten −/− cells. Doxorubicin (also known as hydroxydaunorubicin) is commonly used to treat many solid tumors and hematological malignancies alone or in combination with other chemotherapeutic agents. One of the main anticancer actions of doxorubicin is DNA damageinduced cell apoptosis, yet tumor resistance to apoptosis remains a key impediment to effective treatment with doxorubicin and other cytotoxic drugs. It is reported that miR-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting Pten (50) and that leukemia cells with elevated miR-21 expression and decreased Pten levels are more resistant to daunorubicin (an analog to doxorubicin), whereas Pten inhibition re-sensitizes cells to this chemotherapeutic agent (51) . Our data in this study explicitly demonstrate that miR-21 loss increases doxorubicin-induced apoptosis, in which Pten plays a pivotal role, even when p53, a critical tumor suppressor that regulates apoptosis, is deleted. This result implies that miR-21 targeting is a potential strategy for overcoming chemoresistance in cancer with a loss-of-function p53 mutation, which comprise about half of all human cancers.
Supplementary material
Supplementary Table W1 can be found at http://carcin.oxfordjournals. org/
